These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11906285)

  • 1. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer.
    Matias PM; Carrondo MA; Coelho R; Thomaz M; Zhao XY; Wegg A; Crusius K; Egner U; Donner P
    J Med Chem; 2002 Mar; 45(7):1439-46. PubMed ID: 11906285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.
    Krishnan AV; Zhao XY; Swami S; Brive L; Peehl DM; Ely KR; Feldman D
    Endocrinology; 2002 May; 143(5):1889-900. PubMed ID: 11956172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
    Bohl CE; Wu Z; Miller DD; Bell CE; Dalton JT
    J Biol Chem; 2007 May; 282(18):13648-55. PubMed ID: 17311914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
    Askew EB; Gampe RT; Stanley TB; Faggart JL; Wilson EM
    J Biol Chem; 2007 Aug; 282(35):25801-16. PubMed ID: 17591767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
    Grosdidier S; Carbó LR; Buzón V; Brooke G; Nguyen P; Baxter JD; Bevan C; Webb P; Estébanez-Perpiñá E; Fernández-Recio J
    Mol Endocrinol; 2012 Jul; 26(7):1078-90. PubMed ID: 22653923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
    Sack JS; Kish KF; Wang C; Attar RM; Kiefer SE; An Y; Wu GY; Scheffler JE; Salvati ME; Krystek SR; Weinmann R; Einspahr HM
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4904-9. PubMed ID: 11320241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.
    Zhao XY; Boyle B; Krishnan AV; Navone NM; Peehl DM; Feldman D
    J Urol; 1999 Dec; 162(6):2192-9. PubMed ID: 10569618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
    Duff J; McEwan IJ
    Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.
    Steketee K; Timmerman L; Ziel-van der Made AC; Doesburg P; Brinkmann AO; Trapman J
    Int J Cancer; 2002 Jul; 100(3):309-17. PubMed ID: 12115546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.
    Jääskeläinen J; Deeb A; Schwabe JW; Mongan NP; Martin H; Hughes IA
    J Mol Endocrinol; 2006 Apr; 36(2):361-8. PubMed ID: 16595706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.
    Zhao XY; Malloy PJ; Krishnan AV; Swami S; Navone NM; Peehl DM; Feldman D
    Nat Med; 2000 Jun; 6(6):703-6. PubMed ID: 10835690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation into CAG repeat length variation and N/C terminal interactions in the T877A mutant androgen receptor found in prostate cancer.
    Southwell J; Chowdhury SF; Gottlieb B; Beitel LK; Lumbroso R; Purisima EO; Trifiro M
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):138-46. PubMed ID: 18619542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural features discriminate androgen receptor N/C terminal and coactivator interactions.
    Askew EB; Minges JT; Hnat AT; Wilson EM
    Mol Cell Endocrinol; 2012 Jan; 348(2):403-10. PubMed ID: 21664945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.
    Shah S; Hess-Wilson JK; Webb S; Daly H; Godoy-Tundidor S; Kim J; Boldison J; Daaka Y; Knudsen KE
    Mol Cancer Res; 2008 Sep; 6(9):1507-20. PubMed ID: 18819937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity.
    He B; Gampe RT; Hnat AT; Faggart JL; Minges JT; French FS; Wilson EM
    J Biol Chem; 2006 Mar; 281(10):6648-63. PubMed ID: 16365032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer.
    Céraline J; Erdmann E; Erbs P; Deslandres-Cruchant M; Jacqmin D; Duclos B; Klein-Soyer C; Dufour P; Bergerat JP
    Eur J Endocrinol; 2003 Jan; 148(1):99-110. PubMed ID: 12534363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.